Biomerica, Inc.
BMRAHealthcareNASDAQMedical Devices · Last scanned Sep 8, 2026
Scan Results
Daily timeframeBiomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical. With a market capitalization of $10.6M, it sits in micro-cap territory. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels.
Market Cap
$10.6M
Beta
—
P/E (TTM)
—
P/E (Fwd)
5.92
EPS (TTM)
$-1.30
EPS (Fwd)
$0.39
ROE
-112.1%
ROA
-52.3%
Cash
$1.3M
Total Debt
$2.4M
Free CF
-$2.8M
52W Change
-20.6%
Annual Financials
Cash vs Debt
Where BMRA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BMRA finished 9.45% above its 150-day moving average ($2.01) and 3.29% above its 200-day moving average ($2.13). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BMRA overbought or oversold?
At the September 3, 2026 close, BMRA's RSI(14) was 75.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, BMRA has $1.3M in cash with $2.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$2.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -112.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $5.3M (2023) to $4.5M (2026), a 17% decline worth watching.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BMRA.